Effects of Trimetazidine in Nonischemic Heart Failure: A Randomized Study

详细信息    查看全文

• 作者：José ; Luis Winter ; MD¹ ; ² ; Pablo F. Castro ; MD¹ ; ² ; ^{pcastro@med.puc.cl" class="auth_mail} ; Juan Carlos Quintana ; MD¹ ; ² ; Rodrigo Altamirano ; MD¹ ; ² ; Andres Enriquez ; MD¹ ; ² ; Hugo E. Verdejo ; MD ; PhD¹ ; ² ; Jorge E. Jalil ; MD² ; Rosemarie Mellado ; PhD³ ; Roberto Concepció ; n ; MD⁴ ; Pablo Sepú ; lveda ; MD⁵ ; Victor Rossel ; MD⁶ ; Luis Sepú ; lveda ; MD⁷ ; Mario Chiong ; PhD¹ ; ⁸ ; Lorena Garcí ; a ; PhD¹ ; ⁸ ; Sergio Lavandero ; PhD¹ ; ⁸ ; ⁹
• 关键词：Trimetazidine ; cardiac metabolism ; heart failure
• 刊名：Journal of Cardiac Failure
• 出版年：March, 2014
• 年：2014
• 卷：20
• 期：3
• 页码：149-154
• 全文大小：210 K

文摘

Objectives

Heart failure (HF) is associated with changes in myocardial metabolism that lead to impairment of contractile function. Trimetazidine (TMZ) modulates cardiac energetic efficiency and improves outcomes in ischemic heart disease. We evaluated the effects of TMZ on left ventricular ejection fraction (LVEF), cardiac metabolism, exercise capacity, O₂ uptake, and quality of life in patients with nonischemic HF.

Methods and Results

Sixty patients with stable nonischemic HF under optimal medical therapy were included in this randomized double-blind study. Patients were randomized to TMZ (35 mg orally twice a day) or placebo for 6 months. LVEF, 6-minute walk test (6MWT), maximum O₂ uptake in cardiopulmonary exercise test, different markers of metabolism, oxidative stress, and endothelial function, and quality of life were assessed at baseline and after TMZ treatment. Left ventricular peak glucose uptake was evaluated with the use of the maximum standardized uptake value (SUV) by 18-fluorodeoxyglucose positron emission tomography (¹⁸FDG-PET). Etiology was idiopathic in 85% and hypertensive in 15%. Both groups were similar in age, functional class, LVEF, and levels of N-terminal pro-B-type natriuretic peptide at baseline. After 6 months of TMZ treatment, no changes were observed in LVEF (31 卤 10% vs 34 卤 8%; P聽= .8), 6MWT (443 卤 25 m vs 506 卤 79 m; P聽= .03), maximum O₂ uptake (19.1 卤 5.0 mL kg^鈭? min^鈭? vs 23.0 卤 7.2 mL kg^鈭? min^鈭?; P聽= .11), functional class (percentages of patients in functional classes I/II/III/IV 10/3753/0 vs 7/40/50/3; P聽= .14), or quality of life (32 卤 26 points vs 24 卤 18 points; P聽= .25) in TMZ versus placebo, respectively. In the subgroup of patients evaluated with ¹⁸FDG-PET, no significant differences were observed in SUV between both groups (7.0 卤 3.6 vs 8.2 卤 3.4 respectively; P聽= .47).

Conclusions

In patients with nonischemic HF, the addition of TMZ to optimal medical treatment does not result in significant changes of LVEF, exercise capacity, O₂ uptake, or quality of life.